NEW YORK – T2 Biosystems said on Friday that it is collaborating with Vanderbilt University Medical Center to implement and evaluate the firm's T2Bacteria Panel in clinical settings.
Separately, the company said in a filing with the US Securities and Exchange Commission that it is offering $8.9 million worth of shares of its common stock, supplementing an earlier stock offering. Previously, it had said it would be offering $75 million worth of shares, of which it has sold about $65 million.
As part of the collaboration with VUMC, the medical center will conduct a prospective study to assess the impact of the direct-from-blood T2Bacteria Panel, which can detect five clinically relevant bacterial pathogens, on improving antibiotic usage and clinical interventions for patients with bloodstream infections.
The collaboration "provides a unique opportunity to show the benefit of rapid, culture-independent diagnostics and further demonstrate the value of the T2Bacteria Panel in rapidly identifying causative bacterial pathogens in septic patients," John Sperzel, chairman and CEO of T2 Biosystems, said in a statement.